Vol 5, No 1 (February 2016): Translational Lung Cancer Research (Small Cell Lung Cancer)

Preface on Small Cell Lung Cancer

Preface on small cell lung cancer
Niki Karachaliou, Daniela Morales-Espinosa

Review Article on Small Cell Lung Cancer

Cellular and molecular biology of small cell lung cancer: an overview
Niki Karachaliou, Sara Pilotto, Chiara Lazzari, Emilio Bria, Filippo de Marinis, Rafael Rosell
Cancer stem cells in small cell lung cancer
Jordi Codony-Servat, Alberto Verlicchi, Rafael Rosell
Treatment for small cell lung cancer, where are we now?—a review
Gabriela Alvarado-Luna, Daniela Morales-Espinosa
Small cell lung cancer (SCLC): no treatment advances in recent years
Filippos Koinis, Athanasios Kotsakis, Vasileios Georgoulias
Targeted drugs in small-cell lung cancer
Mariacarmela Santarpia, Maria Grazia Daffinà, Niki Karachaliou, Maria González-Cao, Chiara Lazzari, Giuseppe Altavilla, Rafael Rosell

Original Article on Small Cell Lung Cancer

Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells
Gerhard Hamilton, Barbara Rath, Sophia Holzer, Maximilian Hochmair

Editorial

Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer
Hidehito Horinouchi
Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking
Chuong D. Hoang
AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
Ignacio Gil-Bazo, Christian Rolfo
Raising the bar for enthusiasm when looking at results of randomized phase II trials—the case of sunitinib in small-cell lung cancer
Massimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
AZD9291 in epidermal growth factor receptor inhibitor—resistant non-small-cell lung cancer
Thomas E. Stinchcombe
Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
Jon Zugazagoitia, Santiago Ponce, Luis Paz-Ares
Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?
Kosuke Takahashi, Hiroshi Saito
Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution
Gonzalo Varela, María Teresa Gómez-Hernández
The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung
Wan Ling Tan, Quan-Sing Ng
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
Giuseppe Lo Russo, Claudia Proto, Marina Chiara Garassino
Overall survival in non-small cell lung cancer—what is clinically meaningful?
Klaus Fenchel, Ludger Sellmann, Wolfram C. M. Dempke

Review Article

PiggyBac transposon vectors: the tools of the human gene encoding
Shuang Zhao, Enze Jiang, Shuangshuang Chen, Yuan Gu, Anna Junjie Shangguan, Tangfeng Lv, Liguo Luo, Zhenghong Yu

Letter to the Editor

Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target
Domenico Galetta, Annamaria Catino, Andrea Misino

Case Report

Metachronous primary uterine cancer surgically resected during crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma
Annamaria Catino, Andrea Misino, Anna Scattone, Lucia Caldarola, Stella Petroni, Antonio Logroscino, Elisabetta Sara Montagna, Gabriella Serio, Giovanni Simone, Domenico Galetta